AssetID: 54609149
Headline: UNCAPTIONED: Annual HIV Injection Shows Promise in Early Trial
Caption: Annual HIV Injection Shows Promise in Early Trial. A new once-a-year injection to prevent HIV has passed a crucial early safety trial, according to research published in The Lancet. The drug, called Lenacapavir, works by stopping HIV from replicating inside cells and could become the longest-lasting form of prevention if future trials succeed. Currently, people rely on daily pills or injections every eight weeks for HIV prevention, known as PrEP. While highly effective, daily medication can be hard to maintain. With nearly 40 million people living with HIV, and 65% in Africa, global health agencies like WHO and UNAids are working to end the HIV epidemic by 2030—and innovations like this could be a game changer. Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT
Keywords: Health & Wellbeing,once-a-year,injection,lenacapavir,HIV,protection,prevention,daily,pills,medication,maintin,stops,replicating,inside,cells,AIDS,PrPEP,WHO UNAids,epidemic,game changer
PersonInImage: